Krishna Institute of Medical Sciences Ltd (KIMS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Krishna Institute of Medical Sciences Ltd on NSE and BSE, with an AI summary of each filing.
Investor presentation
Investor Presentation · 05 Nov 2026, 1:47 am
KIMS Hospitals Delivers Strong Q2 FY27 With Revenue Up 41.3% YoY KIMS Hospitals reported total revenue of Rs 13,630 Mn in Q2 FY27, up 41.3% YoY and 14.0% QoQ. EBITDA expanded 34.0% YoY to Rs 2,789 Mn with a 20.5% margin, while PAT rose 5.1% YoY and 102.4% QoQ to Rs 757 Mn. Operational momentum remained robust as IP volumes grew 27.0% YoY to 81,668, OP volumes rose 23.3% YoY to 7,31,010, and ARPOB increased 14.9% YoY to Rs 48,277. The group expanded operational beds to 5,605, advancing its 10,000+ bed capacity roadmap.
Press Release
Press Release · 05 Nov 2026, 1:37 am
KIMS Hospitals Delivers Strong Q2 FY27 Results With 41.3% YoY Revenue Growth KIMS Hospitals reported consolidated total revenue of INR 1,363 Cr for Q2 FY27, up 41.3% YoY and 14.0% QoQ. EBITDA expanded 34.0% YoY to INR 279 Cr with margins at 20.5%. PAT stood at INR 76 Cr versus INR 72 Cr in Q2 FY26. Operationally, IP volumes rose 27.0% YoY to 81,668, OP volumes grew 23.3% YoY to 7,31,010, and ARPOB increased 14.9% YoY to INR 48,277. Cash and equivalents stood at INR 420 Cr as of 30th Sep'26.
Quarterly Result
Financial Result · 05 Nov 2026, 12:31 am
Outcome of the Board Meeting
Outcome · 05 Nov 2026, 12:17 am
KIMS Approves Q2 Results, Key Reappointments, and Subsidiary Merger Krishna Institute of Medical Sciences (KIMS) approved unaudited financial results for the quarter ended 30th Sep'26, posting consolidated revenue from operations of Rs. 13,444 million and net profit of Rs. 746 million. The board cleared the merger of wholly-owned subsidiary KIMS Hospitals Pvt Ltd into the parent company. Additionally, KIMS Swastha entered an O&M agreement for Westfort Hospital, Thrissur. Dr. Bhaskara Rao Bollineni (CMD) and Dr. Abhinay Bollineni (Director & CEO) were reappointed for five-year terms. KIMS also acquired a 51% stake in Sarvottam Health Care for Rs. 795 million.
Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 05 Nov 2026, 12:13 am
General Announcement
Others (Uncategorized) · 01 Nov 2026, 8:56 pm
KIMS Doubles Bed Capacity at Anantapur Facility to 500 Beds Krishna Institute of Medical Sciences Limited (KIMS) announced that its subsidiary, Saveera Institute of Medical Sciences Private Limited, expanded the bed capacity of KIMS Saveera Hospital in Anantapur from 250 to 500 beds on 1st Nov'26. The expansion strengthens tertiary and quaternary healthcare in Andhra Pradesh's Rayalaseema region. Newly inaugurated facilities include a comprehensive Oncology Block equipped with HD-LINAC, Digital PET-CT, and Brachytherapy, alongside a dedicated Mother and Child Block with specialized neonatal intensive care units to enhance clinical capabilities.
The Company ahs acquired 5.82% stake in Ushahkal Abhinav Specialty Hospital LLP (Sangli)
Others (Uncategorized) · 30 Oct 2026, 4:29 am
KIMS Acquires 5.82% Stake in Ushahkal Abhinav Specialty Hospital for ₹15 Crore Krishna Institute of Medical Sciences Limited (KIMS) has acquired a 5.82% strategic stake in Ushahkal Abhinav Specialty Hospital LLP (Sangli) via primary cash infusion of ₹15.00 crore, executed on 29th Oct'26. The target operates a 316-bed quaternary care facility in Maharashtra expandable to over 500 beds. For FY26, the target reported revenue of ₹80.42 crore (up from ₹73.55 crore in FY25 and ₹64.51 crore in FY24), a net loss of ₹23.59 crore, and net worth of ₹116.42 crore. The non-related-party transaction requires no further regulatory approvals.
The Company ahs entered into definitive agreements for acquiring 51% stake in Sarvottam Healthcare Private Limited
Others (Uncategorized) · 30 Oct 2026, 4:26 am
KIMS to Acquire 51% Stake in Sarvottam Health Care for ₹79.50 Crore Krishna Institute of Medical Sciences (KIMS) has signed definitive agreements to acquire a 51.00% equity stake (21,72,713 shares) in Kakinada-based Sarvottam Health Care Private Limited for an aggregate cash consideration of up to ₹79.50 crore. The strategic acquisition exercises a call option under their existing O&M arrangement. Sarvottam operates the 183-bed "Trust Multi Speciality Hospital," posting a turnover of ₹84.83 crore, PAT of ₹7.06 crore, and net worth of ₹50.30 crore in FY26. Share transfers will conclude in due course.
Dr. Bhaskara Rao Bollineni - Founder & Managing Director, Dr. Abhinay Bollineni - Executive Director and CEO, and Mr. Sachin Salvi - Chief Financial Officer, would participate in a conference ....
Intimation · 05 Nov 2026, 10:00 am
KIMS Hospitals Schedules Q2FY27 Earnings Conference Call for 5th Nov'26 Krishna Institute of Medical Sciences Limited will host an earnings conference call on 5th Nov'26 at 10:00 AM IST, organized by IIFL Capital. The leadership team—including Founder & MD Dr. Bhaskara Rao Bollineni, Executive Director & CEO Dr. Abhinay Bollineni, and CFO Sachin Salvi—will participate to discuss the company's business strategy and outlook following the announcement of its Q2FY27 financial results.
General Announcement
Others (Uncategorized) · 29 Oct 2026, 2:04 am
KIMS Clarifies Legal Status on Chennai Land Lease for Super Speciality Hospital The Supreme Court dismissed KIMS's Special Leave Petition on 27th Oct'26 regarding a suit challenging the administration of Andhra Mahila Sabha Trust and its long-term lease of 1.168 acres in Chennai to KIMS for a super speciality hospital. KIMS clarified that proceedings remain pending on merit without any final determination. Crucially, there is no injunction or stay restraining KIMS from proceeding with the project, ensuring the company's rights under the Leave and Licence Agreement and the project's commercial viability remain intact.
KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
Krishna Institute Of Medical Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the unaudited ....
Intimation · 04 Nov 2026, 5:30 am
KIMS Board Meeting Scheduled for Nov'26 to Consider Q2 Results Krishna Institute of Medical Sciences Limited has scheduled a Board of Directors meeting on 4th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for Q2 and the half-year ended 30th Sep'26. Additionally, the trading window for designated persons has been closed from 1st Oct'26 and will reopen 48 hours after the public disclosure of the financial results.
JM Financial Annual India Conference
Intimation · 19 Oct 2026, 5:51 pm
KIMS Schedules Group Meeting at JM Financial Annual India Conference Krishna Institute of Medical Sciences Limited (KIMS) will participate in a group meeting with analysts and institutional investors at the JM Financial Annual India Conference on 16th Nov'26 in Mumbai, India. The company confirmed that no unpublished price-sensitive information (UPSI) will be shared during the event.
General Update
Others (Uncategorized) · 09 Oct 2026, 12:09 am
KIMS Submits Regulatory Clarification on Board Meeting Timings to BSE Krishna Institute of Medical Sciences Limited (KIMS) submitted additional disclosures to BSE regarding its prior corporate announcement on acquisitions dated 6th Oct'26. In response to BSE’s query received on 7th Oct'26 pursuant to SEBI Listing Regulations, the company clarified the specific timings for its board meeting held on 6th Oct'26, confirming it commenced at 02:30 PM and concluded at 05:15 PM.
General Update
Others (Uncategorized) · 07 Oct 2026, 8:19 pm
KIMS Issues Downward Typographical Corrections for Target Entities' Financial Metrics Krishna Institute of Medical Sciences Limited (KIMS) corrected typographical errors regarding target entity financials previously disclosed on 6th Oct'26. For Insignia Healthcare Private Limited, net worth was revised downward from ₹243.3 Cr to ₹24.3 Cr, and turnover was corrected from ₹104.5 Cr to ₹9.68 Cr. Additionally, Sarvottam Health Care Private Limited's PAT was adjusted from ₹70.55 Cr to ₹7.06 Cr. All other terms and figures from the original intimations remain unchanged.
Intimation U/r 30
Others (Uncategorized) · 07 Oct 2026, 1:32 am
KIMS to Acquire Up to 22% Stake in Splendid Hospitals for ₹40 Crore Krishna Institute of Medical Sciences (KIMS) approved a primary cash infusion of up to ₹40.00 Cr to acquire up to a 22% equity stake in Splendid Hospitals Private Limited (Kompally) as a strategic investment. Splendid Hospitals operates a facility expandable to 225+ beds in Telangana and generated turnover of ₹1.39 Cr, a net loss of ₹8.92 Cr, and a net worth of ₹38.69 Cr in FY26. The transaction does not qualify as a related-party deal and is scheduled to close on or before 31st Mar'27.
Intimation U/r 30
Others (Uncategorized) · 07 Oct 2026, 1:30 am
KIMS to Acquire 51% Stake in Sarvottam Health Care for ₹80 Crore Krishna Institute of Medical Sciences (KIMS) approved acquiring up to a 51% equity stake (21,72,713 shares) in its O&M partner, Sarvottam Health Care Private Limited, for an aggregate cash consideration of up to ₹80.00 Cr. The transaction is slated for completion on or before 31st Oct'26. Sarvottam operates the 183-bed Trust Multi Speciality Hospital in Kakinada, Andhra Pradesh, and reported a turnover of ₹84.83 Cr, PAT of ₹70.55 Cr, and a net worth of ₹50.30 Cr for FY26.
Intimation under regulation 30 of SEBI(LODR)
Others (Uncategorized) · 07 Oct 2026, 1:27 am
KIMS Approves 6% Strategic Stake Acquisition in Ushahkal Abhinav Specialty Hospital Krishna Institute of Medical Sciences Limited approved acquiring a 6% stake in Ushahkal Abhinav Specialty Hospital LLP (UAIMS), Sangli, for an aggregate cash consideration of up to ₹15 Crore via primary infusion. The transaction is slated for completion on or before 31st Oct'26. KIMS acts as the exclusive O&M partner managing operations under the "KIMS-UAIMS" brand. The 316-bed quaternary facility (expandable to 500+ beds) posted FY26 turnover of ₹80.42 Crore, PAT of -₹23.59 Crore, and net worth of ₹116.42 Crore.
Intimation u/r 30-acquistion of upto 51 % stake in Insignia
Others (Uncategorized) · 07 Oct 2026, 1:24 am
KIMS Approves Up to 51% Strategic Stake Acquisition in Insignia Healthcare Krishna Institute of Medical Sciences (KIMS) approved acquiring up to a 51.00% equity stake on a fully diluted basis in Insignia Healthcare Private Limited (KIMS-SIKHARA), an O&M entity operating a 150-bed hospital in Guntur, Andhra Pradesh, expandable to 200 beds. The cash transaction will occur via creeping acquisition over 12–24 months at Rs 30.35 per share for the initial tranche. For FY25, Insignia reported a turnover of Rs 104.5 crore, a net loss of Rs 13.28 crore, and a net worth of Rs 243.3 crore.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Acquisition/ Disposal of Shares · 23 Sept 2026, 4:51 pm
Catalyst Trusteeship Discloses 6.66% Share Pledge in Krishna Institute of Medical Sciences Catalyst Trusteeship Ltd, acting as debenture trustee for debenture holders, acquired an encumbrance via pledge over 2,80,08,979 equity shares of Krishna Institute of Medical Sciences Ltd on 18th Sep'26. The pledged shares, representing 6.66% of the company's total and diluted voting capital, were created by Bhaskara Rao Bollineni and Bollineni Seenaiah Naidu. Prior to this transaction, the trustee held zero encumbered shares. The total voting capital remains unchanged at Rs 84.00 cr, comprising 42,00,06,484 equity shares with a face value of Rs 2 each.
Anand Rathi Annual Flagship Conference G-200 Summit 2026
Intimation · 15 Sept 2026, 5:57 pm
KIMS Schedules Analyst and Institutional Investor Group Meeting in Mumbai Krishna Institute of Medical Sciences Limited (KIMS) will participate in a group analyst and institutional investor meeting at the Anand Rathi Annual Flagship Conference G-200 Summit 2026. The meeting is scheduled to take place on 22nd Sep'26 in Mumbai, India. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during the event.
J.P. Morgan India Conference
Intimation · 15 Sept 2026, 5:37 pm
KIMS to Participate in J.P. Morgan India Conference Krishna Institute of Medical Sciences Limited (KIMS) has scheduled an analyst and institutional investor meeting under Regulation 30 of SEBI (LODR) Regulations, 2015. The company will participate in a group meeting at the J.P. Morgan India Conference on 21st Sep'26 in Mumbai, India. KIMS confirmed that no unpublished price-sensitive information (UPSI) will be shared during the interaction.
The Company has entered into Operations and Management Agreement with Sarvottam Health Care Private Limited, Kakinada, Andhra Pradesh.
Others (Uncategorized) · 10 Sept 2026, 11:26 pm
KIMS Signs Operations & Management Agreement with Sarvottam Health Care Krishna Institute of Medical Sciences Limited (KIMS) entered into an exclusive Operations and Management (O&M) agreement on 10th Sep'26 with Sarvottam Health Care Private Limited to operate and manage Trust Multi Speciality Hospital in Kakinada, Andhra Pradesh. The facility features an installed capacity of 183 beds across a G+7 structure. The initial contract term is 5 years, extendable by another 5 years. Under the agreement, KIMS will receive a management revenue fee of 9% of the hospital's total net revenue, expanding its regional operational footprint.
Intimation of schedule of Analyst / Institutional Investor Meeting.
Intimation · 07 Sept 2026, 10:35 pm
KIMS Schedules In-Person Institutional Investor Meeting on 10th Sep'26 Krishna Institute of Medical Sciences Limited (KIMS) will host an in-person Institutional Investor Meeting on 10th Sep'26 starting at 2:30 p.m. IST at KIMS Mahadevpura. Organised by Emkay Global, the interaction includes both group and one-on-one sessions. Discussions will rely solely on publicly available information, with no unpublished price-sensitive information being shared.